{"product_id":"merck-swot-analysis","title":"Merck \u0026 Co. SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. stands as a titan in the pharmaceutical industry, boasting a robust pipeline and strong brand recognition. However, navigating patent cliffs and intense competition presents significant challenges.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind Merck's formidable strengths, potential weaknesses, exciting opportunities, and looming threats? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support your strategic planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Oncology Portfolio led by Keytruda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck's oncology portfolio is a powerhouse, largely driven by Keytruda. This immunotherapy has become a cornerstone of cancer treatment, boasting a wide array of approved uses.\u003c\/p\u003e\n\u003cp\u003eIn the second quarter of 2025, Keytruda alone generated $8.0 billion in sales, marking a robust 9% increase. This performance underscores Keytruda's continued dominance and its critical role in Merck's financial success within the oncology sector.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust and Expanding Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck's pipeline is a significant strength, boasting a robust and expanding portfolio across multiple therapeutic areas. This diversity aims to reduce reliance on any single product.\u003c\/p\u003e\n\u003cp\u003eThe company has strategically focused on developing new growth drivers, particularly in areas like cardiometabolic diseases and respiratory illnesses, alongside its established oncology leadership. This forward-looking approach is key to long-term success.\u003c\/p\u003e\n\u003cp\u003eEvidence of this expansion is compelling: Merck's late-stage pipeline has tripled since 2021. The company anticipates that these new growth drivers could represent a commercial opportunity exceeding $50 billion by the mid-2030s, highlighting substantial future revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Presence in Animal Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's Animal Health division is a significant powerhouse, showcasing robust growth. In the second quarter of 2025, this segment achieved an impressive 11% sales increase, reaching $1.6 billion.\u003c\/p\u003e\n\u003cp\u003eThis strong performance is fueled by a rising demand for livestock products, a key market for Merck. The strategic acquisition of Elanco's aqua business further bolsters this division, diversifying its revenue and solidifying its market position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. demonstrates a robust commitment to Research and Development, consistently allocating substantial resources to the discovery and advancement of novel healthcare solutions. This dedication is evident in their pipeline, which is strengthened through both internal innovation and strategic external collaborations, including recent licensing deals and acquisitions designed to enhance their therapeutic offerings.\u003c\/p\u003e\n\u003cp\u003eThe company's R\u0026amp;D strategy focuses on key areas of unmet medical need, driving progress in oncology, vaccines, and other critical therapeutic categories. For instance, in 2023, Merck reported approximately $13.5 billion in R\u0026amp;D expenses, underscoring their significant investment in future growth and innovation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSignificant R\u0026amp;D Investment:\u003c\/strong\u003e Merck invested around $13.5 billion in R\u0026amp;D for the fiscal year 2023, highlighting a core strategic priority.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Expansion:\u003c\/strong\u003e The company actively pursues pipeline growth through internal discovery efforts and strategic external partnerships, including licensing agreements and acquisitions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFocus on Key Therapeutic Areas:\u003c\/strong\u003e R\u0026amp;D efforts are concentrated on high-impact areas such as oncology, vaccines, and other critical medical fields.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation-Driven Growth:\u003c\/strong\u003e This commitment to R\u0026amp;D is fundamental to Merck's strategy for developing groundbreaking treatments and maintaining a competitive edge.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Acquisitions and Optimization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. is demonstrating a strong commitment to growth through strategic acquisitions, notably the acquisition of Verona Pharma. This move significantly bolsters Merck's presence in the respiratory disease sector, a key therapeutic area.  This proactive portfolio expansion is a core strength, positioning the company for future market leadership.\u003c\/p\u003e\n\u003cp\u003eComplementing its acquisition strategy, Merck has launched a substantial optimization initiative. This plan aims to deliver $3.0 billion in annual cost savings by the conclusion of 2027. These generated savings are earmarked for reinvestment into crucial strategic growth areas, further fueling the company's expansion and innovation efforts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Acquisitions:\u003c\/strong\u003e Verona Pharma acquisition enhances respiratory pipeline.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOptimization Initiative:\u003c\/strong\u003e Targeting $3.0 billion in annual cost savings by end of 2027.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReinvestment Strategy:\u003c\/strong\u003e Savings will be channeled into strategic growth areas.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma Giant's Oncology \u0026amp; Animal Health Drive Strong Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's oncology franchise, led by Keytruda, remains a dominant force, with Q2 2025 sales reaching $8.0 billion, an increase of 9%. The company's pipeline is also a significant strength, having tripled its late-stage assets since 2021, with an anticipated commercial opportunity exceeding $50 billion by the mid-2030s.\u003c\/p\u003e\n\u003cp\u003eThe Animal Health division is another key growth driver, achieving $1.6 billion in sales in Q2 2025, up 11%, bolstered by demand for livestock products and strategic acquisitions like Elanco's aqua business.\u003c\/p\u003e\n\u003cp\u003eMerck's commitment to R\u0026amp;D is substantial, with approximately $13.5 billion invested in 2023, focusing on critical areas like oncology and vaccines. Furthermore, strategic acquisitions, such as Verona Pharma, are enhancing its presence in key therapeutic areas like respiratory diseases.\u003c\/p\u003e\n\u003cp\u003eAn ongoing optimization initiative aims to deliver $3.0 billion in annual cost savings by the end of 2027, with these funds slated for reinvestment into strategic growth areas.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eQ2 2025 Sales (Billions USD)\u003c\/th\u003e\n\u003cth\u003eYoY Growth\u003c\/th\u003e\n\u003cth\u003eKey Drivers\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology (Keytruda)\u003c\/td\u003e\n\u003ctd\u003e8.0\u003c\/td\u003e\n\u003ctd\u003e9%\u003c\/td\u003e\n\u003ctd\u003eBroad approved indications, continued market penetration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnimal Health\u003c\/td\u003e\n\u003ctd\u003e1.6\u003c\/td\u003e\n\u003ctd\u003e11%\u003c\/td\u003e\n\u003ctd\u003eLivestock product demand, Elanco aqua acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a strategic overview of Merck \u0026amp; Co.’s internal strengths, such as its robust R\u0026amp;D pipeline and established market presence, alongside external opportunities like emerging markets and potential new drug approvals, while also addressing weaknesses like reliance on key products and threats from competition and regulatory changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHelps identify and address Merck's competitive vulnerabilities and external threats, offering a clear path to mitigating potential risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Reliance on Keytruda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck's substantial reliance on Keytruda presents a significant weakness. In 2024, Keytruda generated close to half of Merck's total revenue, highlighting its critical importance to the company's financial performance.\u003c\/p\u003e\n\u003cp\u003eThis heavy dependence makes Merck vulnerable, especially with Keytruda's patent expiration looming in 2028. The anticipated arrival of biosimilar competitors post-exclusivity poses a direct threat to its revenue streams and market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeclining Sales of Gardasil\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co. faced a significant hurdle with its Gardasil vaccine line, as sales plummeted by 55% in the second quarter of 2025. This sharp decline was largely attributed to reduced demand in China and the winding down of a national catch-up immunization initiative in Japan, impacting a key revenue driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChallenges in Specific Geographic Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck is encountering significant hurdles in specific geographic territories, notably impacting its Gardasil vaccine sales. In China, elevated channel inventories have led to a suspension of shipments through at least the end of 2025, a critical factor affecting expected revenue streams.\u003c\/p\u003e\n\u003cp\u003eAdding to these regional difficulties, Gardasil is also experiencing slowing revenue growth in Japan. These market-specific challenges highlight the complexities of global pharmaceutical sales and the need for adaptable strategies to navigate diverse economic and regulatory landscapes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of Patent Expirations Beyond Keytruda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMerck is navigating patent expirations for several significant products beyond its blockbuster cancer drug Keytruda. Januvia, a key diabetes medication, is projected to face generic competition and a substantial drop in sales starting in 2026. This situation highlights a broader challenge: Merck must continually innovate and diversify its product pipeline to counteract the revenue erosion from these upcoming patent cliffs.\u003c\/p\u003e\n\u003cp\u003eThe impact of these patent expirations extends beyond a single product, creating a systemic risk for Merck's revenue streams. For instance, Januvia generated approximately $5.3 billion in sales in 2023, and its patent expiration will create a notable void. This necessitates a proactive strategy to bring new, high-value drugs to market and explore strategic acquisitions to maintain growth and market share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eJanuvia's Impending Patent Expiration:\u003c\/strong\u003e Projected to significantly impact sales from 2026 onwards, following Keytruda's own patent considerations.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBroader Portfolio Risk:\u003c\/strong\u003e Multiple key products facing patent expiries create a cumulative revenue challenge for Merck.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNeed for Continuous Innovation:\u003c\/strong\u003e Merck must accelerate its R\u0026amp;D efforts and bring new blockbuster drugs to market to offset anticipated sales declines.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiversification Imperative:\u003c\/strong\u003e Reducing reliance on a few key products through portfolio expansion is crucial for long-term financial stability.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePotential for Regulatory and Pricing Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe pharmaceutical sector is under growing pressure concerning drug pricing and how costs are covered. In the United States, the Inflation Reduction Act (IRA) is set to influence the pricing of key medications, including Merck's blockbuster cancer treatment Keytruda, beginning in 2026. This legislation could significantly impact Merck's financial performance and its ability to invest in new research and development.\u003c\/p\u003e\n\u003cp\u003eThese regulatory shifts present a notable weakness for Merck. The potential for mandated price reductions on high-revenue drugs like Keytruda could directly affect profit margins. For instance, if Keytruda, which generated approximately $25 billion in revenue in 2023, faces price caps under the IRA, it could lead to a substantial decrease in its contribution to Merck's overall earnings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePricing Scrutiny:\u003c\/strong\u003e Increased governmental and public focus on drug affordability.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIRA Impact:\u003c\/strong\u003e The Inflation Reduction Act's negotiation provisions could directly affect revenue from key products like Keytruda starting in 2026.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eReimbursement Challenges:\u003c\/strong\u003e Evolving policies for how drugs are paid for by insurers and government programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eInnovation Funding:\u003c\/strong\u003e Potential reduction in profits could limit future investment in R\u0026amp;D.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRevenue at Risk: Patent Expirations and Product Challenges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck's significant reliance on Keytruda, which accounted for nearly half of its revenue in 2024, creates a substantial vulnerability. This dependence is amplified by Keytruda's patent expiration in 2028, opening the door for biosimilar competition and potential revenue erosion.\u003c\/p\u003e\n\u003cp\u003eThe company is also facing challenges with its Gardasil vaccine, with sales dropping 55% in Q2 2025 due to decreased demand in China and the end of a Japanese immunization initiative. Furthermore, patent expirations for drugs like Januvia, which generated $5.3 billion in 2023, necessitate a constant drive for new product innovation and pipeline diversification.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct\u003c\/td\u003e\n\u003ctd\u003e2023 Revenue (approx.)\u003c\/td\u003e\n\u003ctd\u003eKey Risk\u003c\/td\u003e\n\u003ctd\u003eImpact Timeline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e$25 billion\u003c\/td\u003e\n\u003ctd\u003ePatent Expiration (2028), Biosimilar Competition\u003c\/td\u003e\n\u003ctd\u003ePost-2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanuvia\u003c\/td\u003e\n\u003ctd\u003e$5.3 billion\u003c\/td\u003e\n\u003ctd\u003ePatent Expiration (2026), Generic Competition\u003c\/td\u003e\n\u003ctd\u003eFrom 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil\u003c\/td\u003e\n\u003ctd\u003eN\/A (Significant decline in 2025)\u003c\/td\u003e\n\u003ctd\u003eReduced Demand (China), Program Wind-down (Japan)\u003c\/td\u003e\n\u003ctd\u003eOngoing (2025 onwards)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMerck \u0026amp; Co. SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the same Merck \u0026amp; Co. SWOT analysis document included in your download. The full content is unlocked after payment, giving you a comprehensive understanding of their Strengths, Weaknesses, Opportunities, and Threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55610631192953,"sku":"merck-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/merck-swot-analysis.png?v=1754742014","url":"https:\/\/growthsharematrix.com\/products\/merck-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}